<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>HNN215 Week 7 2pm by </title>
      <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a</link>
      <description>Management of patients experiencing GIT and cellular dysfunction</description>
      <language>en-us</language>
      <pubDate>2023-04-19 02:26:03 UTC</pubDate>
      <lastBuildDate>2023-04-24 05:23:52 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Compare and contrast the significant risks for Tamoxifen</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484430</link>
         <description><![CDATA[<div>What were your significant risks Tamoxifen? Are you able to group these risks?  Why are they significant?<br>Do you understand the MoA of how the patient might develop the risks? <br>Did you need to go and look them up again?&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484430</guid>
      </item>
      <item>
         <title>Significant risks / drug-drug interactions???                           </title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484431</link>
         <description><![CDATA[<div>How / why does it occur?<br>What are they and what signs and symptoms would we see?<br>What do we as nurses do;<br>- prevent and/ or manage these?</div>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/4ab8b0c410f8c88c0082ba8477c9e1f6/image.png" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484431</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484433</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484433</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484435</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484435</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484436</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484436</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484437</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484437</guid>
      </item>
      <item>
         <title>Consider Mrs Marple&#39;s situation...</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484439</link>
         <description><![CDATA[<div><strong><mark>Note: Always consider:<br>Is there anything in the patient's condition/ past history that may increase the risks?</mark></strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484439</guid>
      </item>
      <item>
         <title>Aged patients and medications</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484440</link>
         <description><![CDATA[<div>What factors may result in impaired medication effects in these patients?</div>]]></description>
         <enclosure url="https://image.slideserve.com/1208289/clinical-pharmacokinetics-l.jpg" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484440</guid>
      </item>
      <item>
         <title>Case scenario</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484442</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/bb7439fd8e423f4f26edabe7e234d386/image.png" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484442</guid>
      </item>
      <item>
         <title>Scenario continued</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484445</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/191f187646180640099644033b673d6c/image.png" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484445</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484446</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/ab27431a8ed0067b12d1f8c58563e9d5/HNN215_week_7_NIMC_2023.pdf" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484446</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484449</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/96524290b4fd869a354f71dfc721726e/Nurse_initiated_drug_policy_Deakin_Hospital_2023.pdf" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484449</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484451</link>
         <description><![CDATA[<div><strong>Morphine</strong><br>Morphine promotes the inactivation of tamoxifen through increased glucuronidation<br>Which means the slowed metabolism of morphine in the body<br><strong>MOA</strong><br>Opiod analgesics act on receptors in the CNS and GIT producing analgesia, respiratory depression, sedation and constipation. They act mainly at mu-opioid receptors in the CNS, reducing transmission of the pain impulse and by modulating the descending inhibitory pathways from the brain<br><strong>signs and symptoms</strong>: nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure.&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484451</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484452</link>
         <description><![CDATA[<div>Esomeprazole<br>esomeprazole is a protein pump inhibitor. Binds to the hydrogen/potassium ATPase enzyme system, inhibiting both stimulated and basal acid secretion. Used to treat PUD, GORD, dyspepsia.&nbsp;<br>interactions:&nbsp;<br>- citalopram:&nbsp;increase concentration, increase risk of adverse effects<br>- apalutamide: increases metabolism of drug and may reduce clinical effect&nbsp;<br>- enzalutamide: increases metabolism of drug and may reduce clinical effect&nbsp;<br>- escitalopram: increase concentration and increase risk of adverse effects<br>- tacrolimus: increase concentration which may lead to toxicity<br>nursing management: assess ongoing use of protein pump inhibitors&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484452</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484453</link>
         <description><![CDATA[<div>Naproxen drug class NSAID&nbsp;<br><br>Mode of action&nbsp;<br>Have analgesic, antipyretic and anti-inflammatory actions. they inhibit synthesis of prostaglandins by inhibiting cyclo-oxygenase (COX).<br><br>Indications&nbsp;<br>rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, pain especially due to inflammation.<br><br>Side Effects&nbsp;<br>- nausea<br>- GI ulceration and bleeding<br>- heart failure<br>- hyperkalaemia&nbsp;<br>- renal impariment&nbsp;<br>- confusion&nbsp;<br>- bronchospasm&nbsp;<br>- rash<br><br>nursing consierations&nbsp;<br>- take with or after food&nbsp;<br>- dont adminster to dehydrated patients as it might it increase the risk of side effects.&nbsp;<br>- dont mix it with aspirin for pain as it will increase the risk of side effects&nbsp;<br><br>interactions <br>- Naproxen (NSAIDs)+ ACE inhibitors- NSAIDS may reduce antihypertensive effect of ACE inhibitor and may increase risk of renal impairment and hyperkalaemia.&nbsp;<br>- Naproxen (NSAIDs) + Aspirin- aspirin increases the risk of gastric ulceration. NSAIDs can reduce the antiplatelet activity of low dose aspirin and potentially reduce its cardioprotective effect.&nbsp;<br>- Naproxen (NSAIDs) + Warfarin- NSAIDs increase the risk of serious GI bleeding.<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484453</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484454</link>
         <description><![CDATA[<div>Ondansetron<br>MOA: Central and peripheral 5HT<sub>3</sub> receptor blockade.<br>apomorphine + ondansetron - Severe hypotension, loss of consciousness, bradycardia and seizure activity may result- avoid combination.<br>rifampicin + ondansetron - Rifampicin may increase metabolism of ondansetron, decreasing its efficacy; monitor clinical effect and increase ondansetron dose if necessary<br>tramadol + ondansetron - Ondansetron may decrease tramadol’s analgesic effect (vomiting may also worsen if the tramadol dose is increased to compensate); other 5HT<sub>3</sub> antagonists are likely to behave similarly. Avoid combination or change the antiemetic or opioid if these problems occur.<br><br>Side effects: constipation, headache, dizziness, transient rise in hepatic aminotransferases<br><br>Nursing considerations include assessing pt dizziness to determine if might affect functional ability</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484454</guid>
      </item>
      <item>
         <title>Scenario addition</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484459</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/ca6f1ec54b9fd6e026690ac4490a4253/image.png" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484459</guid>
      </item>
      <item>
         <title>Nurse initiated medication</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484460</link>
         <description><![CDATA[<div><strong>Mrs Marple now has constipation. What medication/s will you give her to relieve this?</strong><br><em>Deakin Hospital Protocol needs to be considered for this decision</em></div>]]></description>
         <enclosure url="https://i.ytimg.com/vi/grQdTmdaQY0/maxresdefault.jpg" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484460</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484461</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484461</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484462</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484462</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484463</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484463</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484464</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-04-19 02:26:03 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2559484464</guid>
      </item>
      <item>
         <title>Group 1 </title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554703</link>
         <description><![CDATA[<div>Tamoxifen<br><br>significant risks:</div><ul><li><a href="https://my.clevelandclinic.org/health/diseases/17675-blood-clots">Blood clots</a>, <a href="https://my.clevelandclinic.org/health/diseases/16911-deep-vein-thrombosis-dvt">deep vein thrombosis</a> (DVT) and <a href="https://my.clevelandclinic.org/health/diseases/5601-stroke-understanding-stroke">strokes</a>.</li><li><a href="https://my.clevelandclinic.org/health/diseases/8589-cataracts">Cataracts</a> or other eye problems.</li><li><a href="https://my.clevelandclinic.org/health/diseases/16409-uterine-cancer">Endometrial (uterine) cancer</a>.</li><li>Menopause-like symptoms,including hot flashes, night sweats and vaginal dryness. Weight gain (more common) or fluid retention (edema). Irregular or loss of menstrual periods.</li></ul><div>- can be grouped as tamoxifen binds to estrogen receptors which produces estrogenic and anti-estrogen effects</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-23 11:03:14 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554703</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554761</link>
         <description><![CDATA[<div>Tamoxifen </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-23 11:03:29 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554761</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554817</link>
         <description><![CDATA[<div>Tamoxifen<br>- Deep Vein Thrombosis&nbsp;<br>- Pulmonary Embolism&nbsp;<br>- Leg Cramps&nbsp;<br>- Alopecia&nbsp;<br>- Loss of Libido<br>- Endometrial Cancer&nbsp;<br>- Angioedema&nbsp;<br>- Hot Flushes&nbsp;<br>- Sweating&nbsp;<br>- Vaginal Discharge&nbsp;<br>- Nausea&nbsp;<br>- Uterine Polyps&nbsp;<br>- Ovarian Cysts&nbsp;<br>- Stroke&nbsp;<br><br>these risks are all related to the blocking of estrogen from performing its duties around the body which are numerous.<br><br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-23 11:03:39 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554817</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554860</link>
         <description><![CDATA[<div>Tamoxifen<br>Risks:&nbsp;<br>- stroke: increased risk of blood clot formation&nbsp;<br>- blood clots: produces oestrogen like effects at some receptors, resulting in increased risk of VTE<br>- cancer of the uterus: offers endometrial cells that contain pre-existing mutations a growth advantage via estrogenetic alterations&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-04-23 11:03:48 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/rccr9k5a6jmm432a/wish/2564554860</guid>
      </item>
   </channel>
</rss>
